What Could Be Propelling Edwards Lifesciences Corp to Decrease?

 What Could Be Propelling Edwards Lifesciences Corp to Decrease?

In today’s session Edwards Lifesciences Corp (EW) recorded an unusually high (929) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious EW decrease. With 929 contracts traded and 13514 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: EW161118P00090000 closed last at: $0.9 or 30.8% down. About 320,366 shares traded hands. Edwards Lifesciences Corp (NYSE:EW) has declined 17.30% since April 20, 2016 and is downtrending. It has underperformed by 21.86% the S&P500.

Edwards Lifesciences Corp (NYSE:EW) Ratings Coverage

Out of 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 19 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 76% are positive. Edwards Lifesciences Corp has been the topic of 52 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Barclays Capital maintained the shares of EW in a report on Wednesday, July 27 with “Equalweight” rating. RBC Capital Markets maintained Edwards Lifesciences Corp (NYSE:EW) rating on Wednesday, February 3. RBC Capital Markets has “Outperform” rating and $100 price target. Zacks downgraded Edwards Lifesciences Corp (NYSE:EW) on Tuesday, September 22 to “Hold” rating. On Monday, April 4 the stock rating was maintained by BMO Capital Markets with “Outperform”. The rating was maintained by Jefferies with “Buy” on Monday, April 4. On Monday, August 10 the stock rating was reinitiated by Credit Suisse with “Outperform”. UBS initiated Edwards Lifesciences Corp (NYSE:EW) on Tuesday, September 22 with “Buy” rating. The firm earned “Buy” rating on Wednesday, July 27 by BTIG Research. Citigroup maintained Edwards Lifesciences Corp (NYSE:EW) on Wednesday, July 27 with “Sell” rating. BTIG Research upgraded the stock to “Buy” rating in Monday, April 4 report.

According to Zacks Investment Research, “Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Company’s products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.”

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The company has a market cap of $17.97 billion. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It has a 33.87 P/E ratio. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

EW Company Profile

Edwards Lifesciences Corporation, incorporated on September 10, 1999, is focused on technologies that treat structural heart disease and critically ill patients. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Firm conducts activities around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

More news for Edwards Lifesciences Corp (NYSE:EW) were recently published by: Wsj.com, which released: “Edwards Lifesciences Shares Fall After-Hours” on October 25, 2016. Investorplace.com‘s article titled: “Why Southwest Airlines Co (LUV), GrubHub Inc (GRUB) and Edwards Lifesciences …” and published on October 26, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment